Armour Thyroid + Levothyroxine
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypothyroidism
Conditions
Hypothyroidism
Trial Timeline
Apr 26, 2024 → Jun 1, 2028
NCT ID
NCT06345339About Armour Thyroid + Levothyroxine
Armour Thyroid + Levothyroxine is a phase 2/3 stage product being developed by AbbVie for Hypothyroidism. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06345339. Target conditions include Hypothyroidism.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06345339 | Phase 2/3 | Recruiting |
Competing Products
5 competing products in Hypothyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Growth hormone + Growth hormone treatment and puberty | Eli Lilly | Approved | 85 |
| iodinated contrast agents | Bayer | Pre-clinical | 20 |
| Iohexol + Iodixanol + Iopromide + Ioversol | Bayer | Approved | 82 |
| Iodinated contrast agents | Bayer | Pre-clinical | 20 |
| levothyroxine sodium | Xeris Pharmaceuticals | Phase 2 | 47 |